Efficacy of Trifecting<sup>®</sup> Night Cream, a Novel Triple acting Skin Brightening Product: A Double-blind, Placebo-controlled Clinical Study.
Jiang. Lily L; Hino. Peter D PD; Bhatia. Ashish A; Stephens. Thomas J TJ; Jimenez. Felipe F
Key Findings
- Both the treatment and control groups showed some skin improvement, likely from the cleanser and sunscreen regimen.
- The group using Trifecting® Night Cream had significantly greater reductions in melasma severity, solar lentigines, and periocular fine lines.
- These improvements were maintained during a four‑week regression period after stopping the cream.
- The study involved only 25 participants (14 on the cream, 11 on placebo) over a 24‑week treatment period.
Practical Outcomes
- For biohackers interested in skin brightening, the data suggest that nightly use of a decapeptide‑12‑containing cream for about six months can meaningfully reduce hyperpigmentation and fine lines, with effects persisting for at least a month after discontinuation. However, the small sample size and commercial nature of the product mean results should be taken as preliminary, and users may want to trial the cream on a small skin area first.
Summary
A 28‑week double‑blind study tested a night cream (Trifecting® Night Cream 1.0) that contains decapeptide‑12 on women with moderate‑to‑severe melasma, sun spots, and eye‑area wrinkles. The cream was applied nightly for 24 weeks, then stopped for four weeks. Participants using the cream showed better improvement in skin dark spots, melasma, and fine lines than those who only used cleanser and sunscreen, and the benefits lasted at least a month after stopping.
Abstract
<b>Background:</b> Melasma is a common, persistent disorder of hyperpigmented facial skin predominantly attributed to ultraviolet light exposure, hormonal influences, and genetic predisposition. <b>Objectives:</b> This double-blind, placebo-controlled, randomized clinical trial was conducted to assess the efficacy and tolerance of a multimodality night cream when used over a course of 24 weeks followed by a four-week regression in female subjects with moderate to severe melasma, presence of solar lentigines, and periocular lines and wrinkles. <b>Methods:</b> Subjects were randomized into one of two groups: Cell 1 received Trifecting<sup>®</sup> Night Cream (Envy Medical, Long Beach, California) 1.0 and Cell 2 did not. All subjects were supplied with a two-product regimen comprising a cleanser and sunscreen to use during the trial. Clinical grading, tolerability assessments, and Chroma Meter measurements (Konica Minolta, Tokyo, Japan) were performed at baseline and at Weeks 8, 16, 24, and 28 (regression). Standardized digital photographs were taken and self-assessment questionnaires were completed. <b>Results:</b> Twenty-five subjects completed the 28-week study, with 14 subjects in Cell 1 and 11 subjects in Cell 2. Subjects in both groups showed improvements in facial conditions. Cell 1 outperformed Cell 2 in improving fine lines, solar lentigines, and melasma conditions. These improvements were sustained during regression period. <b>Conclusions:</b> Trifecting<sup>®</sup> Night Cream 1.0, is effective for the treatment of moderate to severe melasma, solar lentigines, and periocular lines and wrinkles over 24 weeks of usage, with its benefits sustained for at least four weeks after treatment.
Study Information
pubmed
2018
2018-12-01T00:00:00.000Z